Stocks
Funds
Screener
Sectors
Watchlists
HOOK

HOOK - Hookipa Pharma Inc Stock Price, Fair Value and News

$0.96-0.03 (-3.03%)
Market Closed

78/100

HOOK

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

78/100

HOOK

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.41

Target 3M

$1.14

Target 6M

$1.27

HOOK Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

HOOK Price Action

Last 7 days

-3.0%

Last 30 days

9.1%

Last 90 days

9.1%

Trailing 12 Months

-51.0%

HOOK RSI Chart

HOOK Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

HOOK Valuation

Market Cap

10.6M

Price/Earnings (Trailing)

-0.15

Price/Sales (Trailing)

1.15

EV/EBITDA

0.42

Price/Free Cashflow

-0.2

HOOK Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.41

Target 3M

$1.14

Target 6M

$1.27

HOOK Fundamentals

HOOK Revenue

Revenue (TTM)

9.4M

HOOK Earnings

Earnings (TTM)

-73.3M

HOOK Profitability

EBT Margin

-785.15%

Return on Equity

-215.11%

Return on Assets

-119.68%

Free Cashflow Yield

-492.88%

HOOK Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20259.4M000
202453.6M52.2M50.0M43.9M
202316.0M15.9M20.6M20.1M
202214.6M12.0M10.3M14.2M
202121.2M19.9M19.7M18.4M
202013.4M16.0M18.0M19.6M
20199.9M13.3M13.4M11.9M
20180007.6M
HOOK
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
 CEO
 WEBSITEhookipapharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES156

Hookipa Pharma Inc Frequently Asked Questions


HOOK is the stock ticker symbol of Hookipa Pharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Hookipa Pharma Inc is 10.6 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check HOOK's fair value in chart for subscribers.

The fair value guage provides a quick view whether HOOK is over valued or under valued. Whether Hookipa Pharma Inc is cheap or expensive depends on the assumptions which impact Hookipa Pharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HOOK.

As of Wed Jan 28 2026, HOOK's PE ratio (Price to Earnings) is -0.15 and Price to Sales (PS) ratio is 1.15. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HOOK PE ratio will change depending on the future growth rate expectations of investors.